Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Green Planet Bio Engineering Co. Ltd.

Ticker
GPLB
Sector
Industry
Report date
November 13, 2026
Valye AI Score

99

Very high visibility
Recent developments
Recent developments summary

No direct recent business developments or operational updates for Green Planet Bio Engineering Co., Ltd. were found in recent news. The company remains a shell corporation with no active operations.

Recent developments:
  • Green Planet Bio Engineering Co., Ltd. continues to operate as a public shell corporation without active business operations or revenue generation. [S1][S2]
  • The company reported a net loss of $8,440 for the three months ended September 30, 2026, and a net loss of $25,289 for the nine months ended September 30, 2026. [S2]
  • As of September 30, 2026, the company had zero cash and equivalents, zero current assets, and current liabilities of $526,265, resulting in a current ratio of zero. [S2]
  • The company’s stockholders’ deficit was $526,265 as of September 30, 2026. [S2]
  • The company’s common stock is not currently traded on any market and is subject to transfer restrictions. [S1]
  • The company incurs significant costs related to public company compliance, including Sarbanes-Oxley Act requirements. [S1]
  • Recent news coverage does not provide updates on Green Planet Bio Engineering but includes general market and sector news unrelated to the company’s operations. [N1]
Overview

Green Planet Bioengineering Co., Ltd. is a public reorganized shell corporation incorporated in Delaware in 2006. Its stated purpose is to acquire or merge with an existing business operation. Historically, it operated in the agritech sector in China through a subsidiary but divested that business in 2010. Since then, the company has remained a shell entity without active operations. The company’s ability to generate revenue and execute business plans depends on securing adequate financing or identifying profitable business opportunities. It incurs ongoing costs associated with being a public company, including compliance with Sarbanes-Oxley Act requirements. The company’s common stock is subject to transfer restrictions and may be classified as a penny stock. As of the latest filings, the company had no cash or current assets and reported a net loss for the recent quarter and nine-month periods. The company’s stockholders’ deficit reflects accumulated losses and liabilities exceeding assets.

Executive summary

Green Planet Bioengineering Co., Ltd. operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation. The company has no active operating business currently and depends on securing financing or finding profitable business opportunities to generate revenue. As of September 30, 2026, the company reported zero cash and equivalents, zero current assets, current liabilities of $526,265, and a net loss of $8,440 for the quarter. The company’s stockholders’ deficit was $526,265. The company incurs significant costs related to public company compliance and faces risks related to financing and business execution. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. [S1][S2]

Scenarios for GPLB

Bull case model:

The company’s structure as a public shell corporation provides a platform for potential acquisition or merger opportunities. If the company successfully identifies and completes a profitable business acquisition, it could leverage its public status to facilitate growth and capital access. The company’s existing compliance with public company regulations may ease transitions to operating status. However, these opportunities are contingent on securing financing and finding suitable business targets.

Bear case model:

The company faces significant risks due to its lack of active operations and reliance on external financing or acquisition opportunities. Without securing funding or profitable business ventures, the company may continue to incur losses and face delays in executing business plans. The absence of cash and current assets, combined with current liabilities, presents liquidity challenges. Additionally, ongoing public company compliance costs may strain resources. The lack of a trading market and transfer restrictions on shares may limit shareholder liquidity and valuation.

Moat:

Green Planet Bioengineering Co., Ltd. currently operates as a shell corporation without active business operations or proprietary products. Its moat is limited due to the absence of an operating business, revenue streams, or competitive advantages. The company’s value and potential depend on its ability to identify and acquire a profitable business or secure financing to execute a business plan. As such, it does not possess a moat in the traditional sense related to products, technology, or market position.

Risks overview
Risks summary
The primary risk is the company’s dependence on securing financing or profitable business opportunities to transition from a shell corporation to an operating business, compounded by liquidity constraints and ongoing public company costs.
Risks details:

• Financing and Business Execution Risk: The company’s ability to implement business plans and generate revenue depends on securing adequate financing or finding profitable business opportunities. Failure to do so may delay plans and profitability.
• Liquidity Risk: As of September 30, 2026, the company had no cash or current assets and current liabilities of $526,265, resulting in a current ratio of zero, indicating potential liquidity constraints.
• Public Company Compliance Costs: The company incurs significant legal, accounting, and compliance costs related to Sarbanes-Oxley Act and SEC regulations, requiring management attention and financial resources.
• Market and Trading Risks: There is currently no trading market for the company’s common stock, and shares are subject to transfer restrictions. The stock may be classified as a penny stock, subject to additional regulatory requirements, which may affect liquidity and valuation.

FINAL FORECAST FOR GPLB

Final take one line
Green Planet Bio Engineering Co., Ltd. is a public shell corporation with high visibility into its financials and risks but no active operations or revenue generation as of September 2026.
Final take 12 to 24 month view

Business trends: The company remains a shell corporation focused on acquiring or merging with an existing business, with no active operations or revenue generation.
Execution milestones: Key milestones include securing adequate financing or identifying profitable business opportunities to transition to an operating business.
Key risks: Dependence on external financing, liquidity constraints, ongoing public company compliance costs, and lack of a trading market for its stock.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

99
LLM visibility overview
LLM Visibility known facts
  • Green Planet Bioengineering Co., Ltd. operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation.
  • The company was incorporated in Delaware in 2006 and changed its name to Green Planet Bioengineering Co., Ltd. in 2008.
  • Previously, it acquired Elevated Throne Overseas Ltd and its subsidiaries operating in agritech in China but divested this business in 2010.
  • As of the latest filings, the company has no active operating business and focuses on finding profitable business opportunities or securing financing.
  • The company’s ability to generate revenue depends on securing financing or acquiring a business.
  • The company incurs significant costs related to being a public company, including compliance with Sarbanes-Oxley Act requirements.
  • There is no trading market currently for the company’s common stock, and shares are subject to transfer restrictions.
  • The company has not paid dividends and does not anticipate paying dividends in the foreseeable future.
  • The company’s common stock may be classified as a penny stock, subject to additional regulatory requirements.
  • As of September 30, 2026, the company had zero cash and equivalents, zero current assets, and current liabilities of $526,265, resulting in a current ratio and cash ratio of zero.
  • The company reported a net loss of $8,440 for the three months ended September 30, 2026, and a net loss of $25,289 for the nine months ended September 30, 2026.
  • The company had 20,006,402 shares of common stock outstanding as of November 13, 2026.
  • Stockholders’ deficit was $526,265 as of September 30, 2026.
  • The company’s financial statements are prepared under US GAAP and filed with the SEC in Forms 10-K and 10-Q.
  • The company’s management discussion highlights risks related to the ability to secure financing and execute business plans.
  • Recent news coverage does not provide direct updates on Green Planet Bio Engineering but includes general market and sector news.
  • The company’s latest SEC filings were filed on November 13, 2026, providing up-to-date financial and operational disclosures.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought | https://www.nasdaq.com/articles/cathie-wood-goes-bargain-hunting-3-stocks-she-just-bought
  • N2 | 2026-11-13 | www.nasdaq.com | Inter (INTR) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/inter-intr-q3-2026-earnings-call-transcript
  • N3 | 2026-11-13 | www.nasdaq.com | ImmuCell (ICCC) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/immucell-iccc-q3-2026-earnings-call-transcript
  • N4 | 2026-11-13 | www.nasdaq.com | DiaMedica (DMAC) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/diamedica-dmac-q3-2026-earnings-call-transcript
  • N5 | 2026-11-13 | www.nasdaq.com | Milestone Scientific (MLSS) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/milestone-scientific-mlss-q3-2026-earnings-call-transcript
  • N6 | 2026-11-13 | www.nasdaq.com | Twenty One Capital (XXI) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/twenty-one-capital-xxi-q3-2026-earnings-call-transcript
  • N7 | 2026-11-13 | www.nasdaq.com | Stocks Pressured by Rising Bond Yields | https://www.nasdaq.com/articles/stocks-pressured-rising-bond-yields-2
  • N8 | 2026-11-13 | www.nasdaq.com | Corn Posting Friday Strength as Export Business Picks Up | https://www.nasdaq.com/articles/corn-posting-friday-strength-export-business-picks
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine